Conference Roundup

Clinical Guidance

This page contains affiliate links. We may earn a commission at no extra cost to you — see full disclosure below.

ASCO and ENDO 2026: What Clinicians Need to Know From This Year's Data

GLP-1 Doc Clinical Editorial Team

Two of the year's major medical conferences — ASCO (oncology) and ENDO (endocrinology) — presented significant GLP-1-related data in 2026. Here's what clinicians should take away from this year's presentations.

ASCO 2026: cancer risk data

Oncology-focused research presented at ASCO 2026 examined associations between GLP-1 use and reduced risk for certain obesity-associated cancers, including pancreatic, colorectal, and endometrial cancer. This is observational, association-based data rather than interventional cancer-prevention trial evidence — genuinely interesting and worth monitoring, but not yet a basis for prescribing GLP-1s specifically for cancer prevention.

ENDO 2026: fertility, aging, and activity data

Endocrinology-focused presentations covered GLP-1 effects on male fertility markers, biological aging indicators, and physical activity levels in treated patients — an expanding picture of effects beyond the primary weight-management and glycemic indications.

Clinical takeaway: Conference-presented data is preliminary relative to peer-reviewed, published trial results — useful for tracking where the evidence base is heading, but appropriately weighted as emerging rather than established until formal publication and replication.

Gala GLP-1 $179/mo flat

Confirm with your prescribing clinician how emerging research might be relevant to your specific treatment plan.

Compounded formulations are not FDA-approved.

Visit Gala GLP-1 →Paid link

Wellorithm From $147

Board-certified specialists who stay current with evolving clinical evidence.

Compounded formulations are not FDA-approved.

Visit Wellorithm →Paid link

What this means for patient conversations

This emerging data is genuinely exciting context, but it shouldn't drive treatment decisions ahead of your core weight-management or glycemic goals — a useful thing to be aware of, not a reason to start or change treatment on its own.

Important: GLP-1 Doc earns affiliate commissions when you visit a provider through our links. This does not affect pricing or your care. Provider mentions are editorial. We are not a healthcare provider and do not prescribe medications. Always verify a provider's licensing in your state before starting treatment. Medical Disclaimer: Content is for informational purposes only and is not medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication. Compounded GLP-1 medications are not FDA-approved.